Department of Nuclear Medicine, Gaziantep University, 27310, Sahinbey, Gaziantep, Turkey.
Department of Oncology, Gaziantep University, Gaziantep, Turkey.
Ann Nucl Med. 2021 Dec;35(12):1321-1331. doi: 10.1007/s12149-021-01672-x. Epub 2021 Aug 26.
We compared the ability of Ga-FAPI PET//CT with FDG PET/CT imaging techniques to detect additional lesions in breast cancer patients that may affect further chemotherapy options.
A total of 48 patients with breast cancer underwent concurrent Ga-FAPI-04 and FDG PET/CT regardless of whether they had received chemotherapy or not in the last month before imaging. Both modalities were compared according to various parameters: clinical/pathological features, number of lesions detected, activity uptake (SUV), and the effect on the evaluation of response to treatment in the post-chemotherapy group.
This retrospective study included 48 patients with breast cancer (mean age 53.3 ± 11.7 years; IDC 89.6%; ILC 10.4%). In the comparison of both modalities, no statistical significance was obtained in terms of the pathological characteristics of the patients. More lesions were demonstrated in all categorized regions in Ga-FAPI PET/CT imaging with higher uptake values compared to FDG PET/CT in this study. In the treatment response evaluation of the post-chemotherapy group, 12 cases (12/24) who were evaluated as PMR, CMR, or SD according to FDG PET/CT results were later accepted as PD due to newly detected lesions in complementary Ga-FAPI PET/CT imaging and treatment of patients was managed accordingly by clinicians.
It was determined that Ga-FAPI PET/CT was superior to FDG PET/CT in terms of accuracy and it was thought that Ga-FAPI PET/CT could be utilized as an additional complementary imaging to FDG PET/CT. Moreover, Ga-FAPI PET/CT, with its significant theranostic potential, could become a key element in predicting the pathological response of breast cancer patients in further researches.
我们比较了 Ga-FAPI PET//CT 与 FDG PET/CT 成像技术在检测乳腺癌患者可能影响进一步化疗选择的附加病变方面的能力。
共有 48 例乳腺癌患者在最近一个月未接受化疗的情况下同时接受 Ga-FAPI-04 和 FDG PET/CT 检查。根据各种参数比较两种模态:临床/病理特征、检测到的病变数量、活性摄取(SUV),以及对化疗后组治疗反应评估的影响。
这项回顾性研究包括 48 例乳腺癌患者(平均年龄 53.3±11.7 岁;IDC 89.6%;ILC 10.4%)。在两种模态的比较中,患者的病理特征没有统计学意义。与 FDG PET/CT 相比,Ga-FAPI PET/CT 成像显示所有分类区域的病变更多,摄取值更高。在化疗后组的治疗反应评估中,根据 FDG PET/CT 结果评估为 PMR、CMR 或 SD 的 12 例患者(12/24)后来因互补 Ga-FAPI PET/CT 成像中发现新病变而被接受为 PD,临床医生随后根据该结果对患者进行治疗管理。
Ga-FAPI PET/CT 在准确性方面优于 FDG PET/CT,并且 Ga-FAPI PET/CT 可以作为 FDG PET/CT 的附加互补成像方法。此外,Ga-FAPI PET/CT 具有重要的治疗诊断潜力,可能成为进一步研究中预测乳腺癌患者病理反应的关键因素。